Early data for multivariant COVID-19 vaccine booster shows promise, NIHR

The first results of an early trial of a multivariant COVID-19 vaccine booster, launched in September 2021 and supported by the NIHR, has released positive data. US-based biotechnology company Gritstone bio, Inc. in collaboration with The University of Manchester and Manchester University NHS Foundation Trust have announced the initial phase one clinical data shows the vaccine has strong levels of neutralising antibodies. These are similar to approved mRNA vaccines, but up to a 10-fold lower dose in the first 10 individuals.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news